Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)
A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy
Sponsor: Immunovant Sciences GmbH
A PHASE2 clinical study on Graves' Ophthalmopathy, this trial is completed. The trial is conducted by Immunovant Sciences GmbH and has accumulated 12 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Feb 2022 [monthly]
Completed PHASE2
-
Mar 2021 — Jun 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
▶ Show 7 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Apr 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2019 — Apr 2020 [monthly]
Recruiting PHASE2
-
Jul 2019 — Aug 2019 [monthly]
Recruiting PHASE2
-
Jun 2019 — Jul 2019 [monthly]
Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Recruiting PHASE2
First recorded
Apr 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Immunovant Sciences GmbH
For direct contact, visit the study record on ClinicalTrials.gov .